Basilea Pharmaceutica (XSWX:BSLN) Total Assets : CHF173.3 Mil (As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is Basilea Pharmaceutica Total Assets?

Basilea Pharmaceutica's Total Assets for the quarter that ended in Dec. 2023 was CHF173.3 Mil.

During the past 12 months, Basilea Pharmaceutica's average Total Assets Growth Rate was -16.70% per year. During the past 3 years, the average Total Assets Growth Rate was 18.60% per year. During the past 5 years, the average Total Assets Growth Rate was 14.80% per year. During the past 10 years, the average Total Assets Growth Rate was 15.60% per year.

During the past 13 years, Basilea Pharmaceutica's highest 3-Year average Total Assets Growth Rate was 51.10%. The lowest was -12.20%. And the median was 3.60%.

Total Assets is connected with ROA %. Basilea Pharmaceutica's annualized ROA % for the quarter that ended in Dec. 2023 was -21.21%. Total Assets is also linked to Revenue through Asset Turnover. Basilea Pharmaceutica's Asset Turnover for the quarter that ended in Dec. 2023 was 0.36.

Basilea Pharmaceutica Total Assets Historical Data

The historical data trend for Basilea Pharmaceutica's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Basilea Pharmaceutica Total Assets Chart

Basilea Pharmaceutica Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

Get a 7-Day Free Trial

221.47

229.79

247.27

220.85

173.29

Basilea Pharmaceutica Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Assets	Get a 7-Day Free Trial															247.27	236.07	220.85	230.03	173.29

Basilea Pharmaceutica Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Basilea Pharmaceutica's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	-10.002	+	183.291
	=	173.3

Basilea Pharmaceutica's Total Assets for the quarter that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (Q: Dec. 2023 )	+	Total Liabilities (Q: Dec. 2023 )
	=	-10.002	+	183.291
	=	173.3

Basilea Pharmaceutica (XSWX:BSLN) Total Assets Explanation

Total Assets is connected with ROA %.

Basilea Pharmaceutica's annualized ROA % for the quarter that ended in Dec. 2023 is

ROA %	=	Net Income (Q: Dec. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	-42.778	/	( (230.034	+	173.289)	/ 2 )
	=	-42.778	/	201.6615
	=	-21.21 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Basilea Pharmaceutica's Asset Turnover for the quarter that ended in Dec. 2023 is

	Asset Turnover
=	Revenue (Q: Dec. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
=	72.729	/	( (230.034	+	173.289)	/ 2 )
=	72.729	/	201.6615
=	0.36

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Basilea Pharmaceutica Total Assets Related Terms

Thank you for viewing the detailed overview of Basilea Pharmaceutica's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Basilea Pharmaceutica (XSWX:BSLN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Basilea Pharmaceutica Ltd (XSWX:BSLN) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

BSLNz:UK

Address

Switzerland Innovation Park, Basel Area, Main Campus, Near Basel, Allschwil, CHE, 4058

Website

https://www.basilea.com

Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.

Basilea Pharmaceutica (XSWX:BSLN) Headlines

No Headlines